-
Guotan Pharmaceutical "Dual Channel" Management Adjustment!
Time of Update: 2022-05-15
The second is to transfer Eltrombopag ethanolamine tablets in the national medical insurance negotiation drug list to the "dual-channel" management and separate payment list .
-
Hengrui Medicine's Class 1 New Drugs Hit the 30 Billion Antithrombotic Drug Market
Time of Update: 2022-05-15
SHR-2004 Injection Approved Clinical Situation Source: CDE official website According to the announcement, SHR-2004 injection is a macromolecular biological preparation, which is intended to be used for the prevention or treatment of arteriovenous thrombosis .
Market sales of terminal antithrombotic drugs in public medical institutions in China (unit: ten thousand yuan) Source: Minet.
-
A number of top three doctors were punished!
Time of Update: 2022-05-15
In December 2021, according to the website of the Disciplinary and Supervision Commission of Xiaogan City, Hubei Province, six doctors from Xiaogan Central Hospital were warned by the party for accepting meals and gifts from medical representatives in violation of regulations punished and ordered to refund the disciplinary funds .
-
16.3 billion anti-allergic drug market business opportunities are "sensitive"
Time of Update: 2022-05-15
From the perspective of enterprises, there will be 181 manufacturers selling antiallergic drugs in the sample hospitals in 2021, of which the sales of Yangzijiang Pharmaceutical Group (including 4 subsidiaries) will account for 29.
-
Coron will win the $1.5 billion big variety!
Time of Update: 2022-05-15
Recently, Kelun Pharmaceutical entered the administrative examination and approval stage with the imitation of Class 3 Sodium Glucose Injection, which is the second domestic company .
According to the first quarterly report of 2022, Kelun Pharmaceutical's net profit increased by 66.
-
Grasp the new blue ocean of the big health industry to promote economic growth and overtake
Time of Update: 2022-05-15
Since March 2022, a new round of COVID-19 has spread, and China's economic development has been greatly impacted, greatly increasing the downside risks of the macro economy . Coordinating and balan
-
Over 60% of the 73 overseas new drugs urgently needed for clinical use have been approved in China
Time of Update: 2022-05-15
A reporter from the Beijing News sorted out the data based on the Dingxiangyuan Insight database and public information and found that in the three batches of lists, 46 drugs have been approved in China, and metabolic diseases, tumors, and immune system diseases are relatively concentrated treatment areas .
-
CDC: Adenovirus may be the cause of some childhood hepatitis of unknown etiology
Time of Update: 2022-05-14
According to a report released by the US Centers for Disease Control and Prevention on April 29, between October 2021 and February 2022, a total of 9 cases of acute hepatitis of unknown etiology in children with unknown etiology were reported in Alabama, USA, and none of these cases had a history of new crown infection.
-
Cancer Prevention Awareness Week: Microwave Ablation Helps Minimally Invasive Treatment of Tumors
Time of Update: 2022-05-13
In recent years, the development trend of tumor treatment technology in China has been blowout: the treatment methods are constantly enriched, the treatment level is constantly improved, the treatment effect is getting better and better, and the survival period of tumor patients is getting longer and longer, and tumor treatment has entered a new stage of development since then.
-
See how Shante's "prescription" "cures" the "stubborn disease" in the construction of medical informatization
Time of Update: 2022-05-12
Sand Castle series 0-200kVA UPS, through more than 30 years of experience accumulation and advanced digital control technology, further improve the reliability and adaptability of products, and meet the needs of users in the medical industry for power safety and centralized management .
-
The pharmaceutical manufacturing industry grew by nearly 13% in the first two months, and it is expected to continue to develop rapidly throughout the year
Time of Update: 2022-05-11
The data shows that from January to February 2022, the added value of China's pharmaceutical manufacturing industry will maintain double-digit growth, with a year-on-year increase of nearly 13%, a growth rate higher than the national industry 5.
-
10 executives "leave the field" within 10 months, what is this multinational pharmaceutical company doing?
Time of Update: 2022-05-11
. From the perspective of the reasons, the main reason is that the new medical reform policies such as medical insurance negotiation and centralized procurement implemented in China in recent years have had an impact on the company's performance .
-
Sprinting for A+H listing, raising more than 12.5 billion yuan, this week's IPO pharmaceutical companies are concerned
Time of Update: 2022-05-11
According to the prospectus, Nuocheng Jianhua plans to raise 4 billion yuan on the Science and Technology Innovation Board for new drug research and development projects, drug research and development platform upgrade projects, marketing network construction projects, informatization construction projects and supplementary working capital .
-
A number of chain cancellations have intensified competition in the pharmacy market
Time of Update: 2022-05-11
[Pharmaceutical Network Market Analysis] Recently, the Hubei Provincial Food and Drug Administration issued an announcement stating that according to relevant regulations, the enterprise decided to cancel the "Drug Business License" of Hubei Yifeng Alkang Pharmacy Chain Co.
-
The prosperity of the innovative drug industry is gradually heating up, and pharmaceutical companies are accelerating their efforts to the field of FIC research and development
Time of Update: 2022-05-11
R&D investment has continued to increase, and at the same time, a large number of companies have actively introduced clinical-stage products through authorized cooperation, resulting in the continuous emergence of first-in-class and fast-follower drugs in the domestic market .
-
Shares of these pharmaceutical stocks hit a one-year high
Time of Update: 2022-05-11
[Pharmaceutical Network Pharmaceutical Stock Market] According to data from Flush, as of April 12, 2022, the stock prices of many pharmaceutical stocks such as Kangyuan Pharmaceutical, China Resources Shuanghe, Dali Pharmaceutical, and First Medicine have reached a new high in one year .
-
The science and technology innovation board index system continues to improve, becoming an important listing place for biopharmaceutical companies
Time of Update: 2022-05-11
Analysts pointed out that the current listed biopharmaceutical companies on the Science and Technology Innovation Board have the attributes of low valuation, high growth, and high R&D, and the investment value is obvious .
-
Traditional Chinese medicine is expected to usher in a new round of development opportunities, and many pharmaceutical companies have locked in expectations for performance growth in the first quarter
Time of Update: 2022-05-11
Pien Tze Huang recently released the 2022 first quarter performance forecast, showing that the company expects a pre-increase in the first quarter of 2022, and the net profit attributable to shareholders of listed companies will increase by 20% to 24% year-on-year, to 678 million to 701 million yuan .
-
Medical insurance pressure will become the norm, and the industry is generally optimistic about investment opportunities in the upstream pharmaceutical supply chain
Time of Update: 2022-05-11
The agency estimates that the market space for equipment and consumables brought by the production of domestic biological drugs has reached 70.
-
Head biotechs with good business continue to be optimistic about maintaining the "overweight" rating of these pharmaceutical companies
Time of Update: 2022-05-11
In addition, Keji Pharmaceutical has continued to increase investment in research and development, which has laid a solid foundation for its technical strength in the industry .
